Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06223607 · ClinicalTrials.gov registry record
Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia
A clinical trial, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 300
- Enrollment target
NCT06223607: Recruiting study, sponsored by Methodist Health System.
NCT06223607 is a clinical trial that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06223607 is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
Study Summary
The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).
Primary Outcome
To evaluate the difference in bleeding rates in patients with chronic thrombocytopenia maintained on DAPT with clopidogrel compared to patients maintained on DAPT with ticagrelor.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-08-22 |
| Est. Completion | 2027-12-22 |
What NCT06223607 shows while recruiting
NCT06223607 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06223607 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06223607 about?
NCT06223607 is a clinical study titled "Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia". The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).
What is the current status of trial NCT06223607?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2022-08-22. Estimated completion is 2027-12-22.
Who is sponsoring clinical trial NCT06223607?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI